DermTech: Michael Howell

DermTech has appointed Michael Howell as CSO, a role in which he will coordinate research, new product development, and clinical validation efforts. Howell has over twenty years of academic and pharmaceutical industry experience. Prior to joining DermTech, he was the translational research lead for inflammation and autoimmunity at Incyte, driving the strategic expansion of Incyte’s pipeline in dermatology and other immunological disorders. Prior to that, he held various other roles within the pharmaceutical industry at Boehringer Ingelheim, Immune Tolerance Network, and MedImmune/AstraZeneca. Howell also served as a faculty member in the Division of Allergy and Immunology at National Jewish Health. He earned a bachelor of science degree in biology from Messiah College and a doctorate in immunology from West Virginia University School of Medicine.